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S mall airway diseases requiring surgical interven-tion are generally treated with surgery in opera-
ble patients.  However,  in some cases,  such as inoper-
able patients,  pediatric patients,  and lung transplant 
recipients with airway complications,  bronchoscopic 
intervention including airway stenting is suitable.  
Among these situations,  airway complications after 
lung transplantation (LT) could be life-threatening 
[1-3],  necessitating careful treatment with broncho-
scopic intervention.  In living-donor lobar LT,  which 
is an established alternative to solve donor shortages 
exclusively in Japan,  airway complications commonly 
develop in the lobar to segmental bronchi,  since the 
right and left lower lobes from two healthy donors are 
implanted in the recipient in place of the whole lungs.  
These lesions are small both in diameter and length,  
necessitating small airway stents.  Although various 
types of airway stents,  including self-expandable 
metallic stents,  silicone stents and biodegradable 
stents,  are currently applied for patients with airway 
diseases [4-7],  these types of airway stents are often 
too large to ﬁt inside small airways.
　 Similar to the airway complications after living-do-
nor lobar LT,  congenital tracheal stenosis in pediatric 
patients is a small airway disease that can be treated 
using small airway stents.  For the treatment of con-
genital tracheal stenosis,  a balloon-expandable metallic 
stent (BEMS) has been shown to provide favorable 
short- and long-term outcomes [8-10].  In general,  
BEMS is used as a vascular stent for peripheral blood 
vessels,  such as the femoral artery and the renal 
artery,  and its safety as a vascular stent is described 
previously [11-14].  Accordingly,  BEMS is smaller 
than conventional airway stents and can also be safely 
and easily deployed using a bronchoscope [8-10,15].  
Despite advisories to restrain from using metallic 
stents for the treatment of benign airway diseases 
[16],  airway complications after LT have been 
treated with self-expandable metallic stents [6,7],  
since immunosuppression therapy after lung transplan-
tation can inhibit granulation tissue formation in the 
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metallic stents [17].  Only BEMS is currently avail-
able for the treatment of small airway diseases;  
therefore,  BEMS could be a valuable treatment 
option for airway complications after living-donor 
lobar LT as well as for pediatric airway diseases and 
airway malignancies in inoperable patients [18,19].  
However,  few studies have examined the safety and 
eﬃcacy of BEMS for the treatment of airway dis-
eases,  prompting us to launch the current study.
Endpoints
　 The present study will evaluate the eﬃcacy and 
safety of BEMS for the treatment of airway complica-
tions after LT,  pediatric airway diseases,  and airway 
malignancies.  The primary endpoint will be the clini-
cal success rate (calculated as the ratio of the number 
of patients with clinical success to the number of reg-
istered patients) on the ﬁrst postoperative day.  The 
secondary endpoints will include the re-stenosis rate,  
adverse event rate,  overall survival (OS),  clinical 
symptoms,  pulmonary function,  the location of the 
stent placement,  and the number of stents used during 
the follow-up period,  which will consist of 5 to 10 
years,  depending on the timing of patient registration 
in this study.
Study Design
　 We have launched a single arm,  prospective,  
non-randomized,  uncontrolled,  open label,  single-cen-
ter study.  The trial is registered at UMIN clinical 
trials registry,  Japan (UMIN000015197).  Fig.  1 
shows an overview of the study design.
Eligibility Criteria
　 All the patients who meet the main inclusion and 
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Fig. 1　 Overview of the study design.  LT,  lung transplantation.
exclusion criteria will be invited for screening.  The 
main inclusion and exclusion criteria are listed in 
Table 1.  This study was conducted in compliance with 
the principles of the Declaration of Helsinki,  and the 
study protocol has been approved by the institutional 
review board of Okayama University Hospital (No.  
m12006).
Treatment Methods
　 Screening will be performed within 7 days before 
stenting.  After admission to our hospital on the day 
before stenting,  the BEMS will be placed in position 
using a rigid or ﬁberoptic bronchoscope while the 
patient is under general anesthesia.  First,  a guide 
wire will be passed through the target airway lesion,  
and the lesion will be dilated with a balloon catheter if 
required.  Next,  depending on the diameter of the 
lesion as estimated using chest computed tomography 
(CT),  an Express Vascular SD stent or an Express 
Vascular LD stent (Boston Scientiﬁc Japan Co.,  
Tokyo,  Japan) mounted on another deﬂated balloon 
catheter (the stent delivery catheter) will be posi-
tioned within the lesion.  The exact site for the stent-
ing will be determined by the simultaneous use of 
bronchoscopy and ﬂuoroscopy.  Finally,  the balloon on 
the stent delivery catheter will be inﬂated,  allowing 
the stent to expand in size in the proper position.  All 
the patients will be followed for 5 to 10 years after 
stenting.  All the procedures will be performed with an 
adequate understanding,  and written informed consent 
will be obtained from the patient by an investigator 
before any screening or inclusion procedures are per-
formed.
Statistical Consideration
　 For the primary endpoint,  clinical success will be 
deﬁned as follows: conﬁrmation of the re-opening of 
the airway lesion using a bronchoscope immediately 
after stent placement,  and conﬁrmation of stent 
patency using a chest radiograph taken on the ﬁrst 
postoperative day.  For the secondary endpoint,  
re-stenosis will be assessed using chest CT examina-
tions during the follow-up period.  An OS curve will be 
constructed using the Kaplan-Meier product-limit 
method and GraphPad Prism (GraphPad Software,  
CA,  USA).
　 We assume that 30 patients will be registered in 
this study.  Based on the number of LT cases treated 
at our hospital,  100 LT cases will likely be performed 
during the 5-year period until September 30,  2019;  
according to our historical data,  10  of LT recipi-
ents (10 patients) are likely to develop airway compli-
cations [20,21].  In addition,  10 former LT recipi-
ents are likely to encounter airway complications,  and 
10 patients with other airway diseases are likely to 
require stent placement during the registration 
period.
　 This study will be performed between September 
17,  2014,  and September 30,  2024.
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Table 1　 Patient eligibility
Inclusion criteria
 1) Airway complications after lung transplantation,  airway malignancies,  or pediatric airway diseases
 2) Airway diseases conﬁrmed using chest CT or bronchoscopy
 3) No indications for other surgical treatments or conventional airway stenting
 4) Adequate hemopoietic functions as follows: leukocytes 2,000/µL,  platelets 30,000/µL,  hemoglobin 6.0 g/dL
 5) Patients can be included regardless of whether they have a history of airway stent placement
Exclusion criteria
 1) Severe myelosuppression,  renal injury or liver injury
 2) Broncho-esophageal or broncho-vascular ﬁstula
 3) Contraindications for bronchoscopy
 4) Severe heart diseases
 5) Severe mental diseases
 6) Other factors making the individual unsuitable for enrollment in the study
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